BR0008439A - Antiandrogênio tópico para perda de cabelo e outras condições hiperandrogênicas e formulação cosmética ou farmacêutica compreendendo o mesmo - Google Patents

Antiandrogênio tópico para perda de cabelo e outras condições hiperandrogênicas e formulação cosmética ou farmacêutica compreendendo o mesmo

Info

Publication number
BR0008439A
BR0008439A BR0008439-5A BR0008439A BR0008439A BR 0008439 A BR0008439 A BR 0008439A BR 0008439 A BR0008439 A BR 0008439A BR 0008439 A BR0008439 A BR 0008439A
Authority
BR
Brazil
Prior art keywords
cosmetic
pharmaceutical formulation
same
hair loss
androgen
Prior art date
Application number
BR0008439-5A
Other languages
English (en)
Other versions
BRPI0008439B1 (pt
Inventor
Milos Sovak
Allen L Seligson
James Gordon Douglas Iii
Brian Campion
Original Assignee
Biophysica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophysica Inc filed Critical Biophysica Inc
Publication of BR0008439A publication Critical patent/BR0008439A/pt
Publication of BRPI0008439B1 publication Critical patent/BRPI0008439B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"ANTIANDROGêNIO TóPICO PARA PERDA DE CABELO E OUTRAS CONDIçõES HIPERANDROGêNICAS E FORMULAçãO COSMéTICA OU FARMACêUTICA COMPREENDENDO O MESMO". A presente invenção refere-se a um composto 2-hidróxi-2-metilN-(4-X-3-(trifluormetil)fenil)-3-(2,2,2-perfluoracilamino) propionamida) aplicado topicamente, especificamente inibe e/ou elimina receptores cutâneos de androgênio e, a seguir, descoberto uso cosmético em aflições na pele associadas com excesso de androgênios, tais como eflúvio capilar, hirsutismo, acne e alopecia androgênica.
BRPI0008439A 2000-02-11 2000-05-25 antiandrogênico tópico, formulação cosmética, uso dos mesmos e método não-terapêutico redução cosmética de eflúvio androgênico e/ou alopecia BRPI0008439B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/502,376 US6472415B1 (en) 1998-12-18 2000-02-11 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
PCT/US2000/014792 WO2001058854A1 (en) 2000-02-11 2000-05-25 A topical antiandrogen for hair loss and other hyperandrogenic conditions

Publications (2)

Publication Number Publication Date
BR0008439A true BR0008439A (pt) 2002-04-23
BRPI0008439B1 BRPI0008439B1 (pt) 2016-04-19

Family

ID=23997526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0008439A BRPI0008439B1 (pt) 2000-02-11 2000-05-25 antiandrogênico tópico, formulação cosmética, uso dos mesmos e método não-terapêutico redução cosmética de eflúvio androgênico e/ou alopecia

Country Status (19)

Country Link
US (1) US6472415B1 (pt)
EP (1) EP1169301B1 (pt)
JP (1) JP4806508B2 (pt)
KR (1) KR100508681B1 (pt)
CN (1) CN100402492C (pt)
AT (1) ATE259781T1 (pt)
AU (3) AU2000253026A1 (pt)
BR (1) BRPI0008439B1 (pt)
CA (1) CA2400185C (pt)
CZ (1) CZ301910B6 (pt)
DE (2) DE60008360T2 (pt)
ES (2) ES2187390B2 (pt)
HK (2) HK1043692A1 (pt)
IL (2) IL145728A0 (pt)
MX (1) MXPA01006376A (pt)
PL (1) PL201173B1 (pt)
RU (1) RU2225390C2 (pt)
WO (2) WO2001058854A1 (pt)
ZA (1) ZA200206497B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828458B2 (en) * 2000-05-25 2004-12-07 Biophysica, Inc. Topical antiandrogen for hair loss and other hyperandrogenic conditions
FR2826263B1 (fr) * 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un compose anti-inflammatoire
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
WO2005000795A2 (en) * 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
US7483554B2 (en) * 2003-11-17 2009-01-27 Aureon Laboratories, Inc. Pathological tissue mapping
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7505948B2 (en) * 2003-11-18 2009-03-17 Aureon Laboratories, Inc. Support vector regression for censored data
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
AU2004305075A1 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
CA2557716A1 (en) * 2004-02-27 2005-09-15 Aureon Biosciences Corporation Methods and systems for predicting occurrence of an event
EP1789923A1 (en) * 2004-08-11 2007-05-30 Aureon Laboratories, Inc. Systems and methods for automated diagnosis and grading of tissue images
CA2587678C (en) * 2004-11-16 2013-05-21 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
FR2878155A1 (fr) * 2004-11-22 2006-05-26 Oreal Protection de la peau contre les alterations liees a un dysfonctionnement des mecanismes physiologiques d'apoptose
WO2006053789A1 (en) * 2004-11-22 2006-05-26 L'oreal Protection of the skin against deterioration linked to a stress-induced dysfunction of the apoptotic and immune defence processes
WO2006053790A1 (en) * 2004-11-22 2006-05-26 L'oreal Use of compounds of the n-acylaminoamide family as soothing or calming agents
FR2878156A1 (fr) * 2004-11-22 2006-05-26 Oreal Utilisation des composes de la famille des n-acylamino-amides comme agents apaisants
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US20070048246A1 (en) * 2005-09-01 2007-03-01 Biophysica Research, Inc. Novel skin care compositions
WO2007057909A1 (en) * 2005-11-21 2007-05-24 Hadasit Medical Research Services & Development Ltd. Androgen-receptor (ar) ligands for use in the treatment and diagnosis of ar-related pathologies
HUE027894T2 (en) 2006-03-27 2016-11-28 Univ California An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases
SG10201408699TA (en) * 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
WO2008044033A1 (en) * 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
GB0722088D0 (en) * 2007-11-09 2007-12-19 Spirogen Ltd Pyrrolobenzodiazepines
NZ586913A (en) 2007-12-21 2012-06-29 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
EP3124481B1 (en) 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
CA3021290C (en) * 2010-09-27 2021-05-25 E. I. Du Pont De Nemours And Company Method for preparing 2-amino-n-(2,2,2-trifluoroethyl)acetamide
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2650678C2 (ru) * 2013-12-31 2018-04-17 Ипсен Фарма С.А.С. Новые производные имидазолидин-2,4-дионов
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AU2017278314B2 (en) * 2016-06-10 2022-06-30 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
EP3886853A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
KR102417496B1 (ko) 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
JPH05194204A (ja) * 1992-01-20 1993-08-03 Lion Corp 抗男性ホルモン剤
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE69709752T2 (de) * 1996-06-27 2002-07-18 Ligand Pharm Inc Androgen rezeptor modulator verbindungen und verfahren
JP3568325B2 (ja) * 1996-07-12 2004-09-22 株式会社ノエビア 抗アンドロゲン剤及び養毛剤並びに毛髪用化粧料
US6184249B1 (en) * 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes

Also Published As

Publication number Publication date
DE10084380T1 (de) 2002-06-20
WO2001058855A1 (en) 2001-08-16
ZA200206497B (en) 2003-08-14
EP1169301A1 (en) 2002-01-09
RU2225390C2 (ru) 2004-03-10
WO2001058854A1 (en) 2001-08-16
IL145728A0 (en) 2002-07-25
ES2187390B2 (es) 2004-04-01
ES2187390A1 (es) 2003-06-01
ATE259781T1 (de) 2004-03-15
AU3685601A (en) 2001-08-20
DE60008360D1 (de) 2004-03-25
DE60008360T2 (de) 2004-12-09
JP2003522752A (ja) 2003-07-29
CA2400185A1 (en) 2001-08-16
BRPI0008439B1 (pt) 2016-04-19
HK1051849A1 (en) 2003-08-22
HK1043692A1 (zh) 2002-09-20
EP1169301B1 (en) 2004-02-18
CZ20012398A3 (cs) 2001-11-14
PL350356A1 (en) 2002-12-02
MXPA01006376A (es) 2003-06-06
PL201173B1 (pl) 2009-03-31
JP4806508B2 (ja) 2011-11-02
CN1416416A (zh) 2003-05-07
US6472415B1 (en) 2002-10-29
CZ301910B6 (cs) 2010-07-28
AU2001236856B2 (en) 2005-08-11
CN100402492C (zh) 2008-07-16
CA2400185C (en) 2011-07-05
KR20020089347A (ko) 2002-11-29
ES2215672T3 (es) 2004-10-16
AU2000253026A1 (en) 2001-08-20
IL145728A (en) 2008-04-13
WO2001058855A9 (en) 2002-10-31
KR100508681B1 (ko) 2005-08-17

Similar Documents

Publication Publication Date Title
BR0008439A (pt) Antiandrogênio tópico para perda de cabelo e outras condições hiperandrogênicas e formulação cosmética ou farmacêutica compreendendo o mesmo
EP0934742A3 (en) High glycerin containing anti-microbial cleansers
BR0108347B1 (pt) composição de cosmético
TR200002204T2 (tr) Bit ve bit yumurtalarının öldürülmesi için terpen uygulaması.
DE69717095D1 (de) Topische vitamin d zusammensetzung auf liposomenbasis
CY1106089T1 (el) Σκευασματα για τοπικη εφαρμογη ουσιων που δρουν ως αντιανδρογονα
WO2004005407A3 (fr) Composés tétraazapentaméthiniques et leur application pour la teinture des fibres keratiniques
DK1047397T3 (da) Topiske præparater til forögelse af glutathionproduktion
WO2004103290A3 (en) Compositions comprising an amidine and an alkane polyol
AU5792399A (en) Stable ascorbic acid preparation for topical use
ATE259210T1 (de) Trichologische lotion für die topische anwendung
BRPI0406832A (pt) Método de reduzir o crescimento de pêlos em um ser humano, uso de um conjugado de alfa-difluorometilornitina ou um sal farmaceuticamente aceitável do mesmo, composto, composição, e, uso de um composto
DE60010204T2 (de) Sonnenschutzzusammensetzungen und deren verwendung
CA2280985A1 (fr) Composition contenant de l'uree et ses utilisations dans le domaine cosmetique et/ou dermatologique
BR0211778A (pt) Método para reduzir o crescimento capilar humano, composição para a aplicação tópica à pele, uso de uréia, e, método para produzir uma composição para inibir o crescimento capilar de mamìfero
BR0000627B1 (pt) composiÇço cosmÉtica para uso tàpico, uso da composiÇço e processo de tratamento cosmÉtico.
ATE350106T1 (de) Veterinärmedizinische dermatologische zusammensetzung
AR032762A1 (es) 2-hidroxi-3-perfluoracilaminopropionamidas topico para la perdida del cabello y otras condiciones hiperandrogenicas, una formulacion cosmetica y farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
BR0009860B1 (pt) composiÇço cosmÉtica para uso tàpico e uso da composiÇço.
BR9203266A (pt) Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
BR0105926A (pt) Composição cosmética ou farmacêutica útil na inibição ou retardamento de alopecia humana por meio de aplicação tópica da composição
ES2152187B1 (es) Locion estimulante del foliculo piloso.
KR860000062A (ko) 엘라스타제 양모제
TH65361A (th) สารผสมที่ใช้กับเส้นผม
BR0303724A (pt) Composição e método para tratamento de lipodistrofia ginoide

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/04/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.